Literature DB >> 11450706

Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.

H Zhou1, V Shen, D W Dempster, R Lindsay.   

Abstract

Generally, it is believed that intermittent administration of parathyroid hormone (PTH) has an anabolic effect on the skeleton, whereas continuous administration is catabolic. However, there is evidence that continuous exposure to PTH may have an anabolic effect, for example, in patients with mild primary hyperparathyroidism (PHPT). The possibility of delivering PTH continuously may have important implications for the treatment of osteoporosis. Furthermore, estrogen treatment may be useful in the medical management of PHPT. Therefore, we examined the skeletal effects of continuous administration of PTH, with or without estrogen, in the estrogen-deficient rat with established osteopenia. Forty 7-month-old SD rats were divided into four ovariectomy (OVX) groups and one sham-operated group. Eight weeks post-OVX, three groups received subcutaneous implants of Alzet mini pumps loaded with PTH(1-34) (30 microg/kg per day), 17beta-estradiol (10 microg/kg per day) pellet, or both PTH and 17beta-estradiol separately for 4 weeks. OVX and sham control groups were given the mini pumps loaded with vehicle. Two doses of calcein (10 mg/kg) were given subcutaneously to all rats 2 days and 8 days before death. Histomorphometry was performed on cancellous and cortical bone of the fourth lumbar vertebra. At 3 months, post-OVX rats displayed bone loss with high bone turnover. Estrogen reversed OVX-mediated high turnover without restoring cancellous bone volume (BV/TV). PTH infusion further increased bone turnover and partially restored BV/TV. However, PTH infusion increased cortical porosity. Estrogen inhibited PTH-mediated cancellous bone resorption and substantially increased BV/TV above sham control. The combined treatment was associated with a significant increase in peritrabecular fibrosis and woven bone formation. The combined treatment of PTH infusion and estrogen replacement enhanced cortical width but estrogen did not prevent the PTH-induced cortical tunneling. We conclude that continuous administration of PTH and estrogen increases cortical porosity but has substantial beneficial effects on vertebral cancellous bone volume and cortical width in OVX rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11450706     DOI: 10.1359/jbmr.2001.16.7.1300

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  Mechanisms of bone loss and gain in untreated and treated osteoporosis.

Authors:  Juliet Compston
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

2.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

3.  The calcium-sensing receptor complements parathyroid hormone-induced bone turnover in discrete skeletal compartments in mice.

Authors:  Yingben Xue; Yongjun Xiao; Jingning Liu; Andrew C Karaplis; Martin R Pollak; Edward M Brown; Dengshun Miao; David Goltzman
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-01-24       Impact factor: 4.310

4.  Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.

Authors:  Makoto Okazaki; Sebastien Ferrandon; Jean-Pierre Vilardaga; Mary L Bouxsein; John T Potts; Thomas J Gardella
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

5.  Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss.

Authors:  Brahmchetna Bedi; Jau-Yi Li; Francesco Grassi; Hesham Tawfeek; M Neale Weitzmann; Roberto Pacifici
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

6.  Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone.

Authors:  Chandrika D Mahalingam; Tanuka Datta; Rashmi V Patil; Jaclynn Kreider; R Daniel Bonfil; Keith L Kirkwood; Steven A Goldstein; Abdul B Abou-Samra; Nabanita S Datta
Journal:  J Endocrinol       Date:  2011-08-18       Impact factor: 4.286

7.  The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.

Authors:  Teruyo Nakatani; Tiffany Chen; Joshua Johnson; Jennifer J Westendorf; Nicola C Partridge
Journal:  J Bone Miner Res       Date:  2018-04-25       Impact factor: 6.741

8.  Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

Authors:  Daniel Cejka; Diego Parada-Rodriguez; Stefanie Pichler; Rodrig Marculescu; Ina Kramer; Michaela Kneissel; Thomas Gross; Andreas Reisinger; Dieter Pahr; Marie-Claude Monier-Faugere; Martin Haas; Hartmut H Malluche
Journal:  Kidney Int       Date:  2016-08-12       Impact factor: 10.612

9.  T cells potentiate PTH-induced cortical bone loss through CD40L signaling.

Authors:  Yuhao Gao; Xiaojun Wu; Masakazu Terauchi; Jau-Yi Li; Francesco Grassi; Sarah Galley; Xiaoying Yang; M Neale Weitzmann; Roberto Pacifici
Journal:  Cell Metab       Date:  2008-08       Impact factor: 27.287

10.  Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration.

Authors:  Mami Ogita; Marie Therese Rached; Elzbieta Dworakowski; John P Bilezikian; Stavroula Kousteni
Journal:  Endocrinology       Date:  2008-07-10       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.